Fibroblast growth factor receptor (FGFR)-selective tyrosine kinase inhibitors (TKI), such as infigratinib, show potency and selectivity for FGFR3 at pharmacologically 'relevant doses for the potential treatment of achondroplasia (ACH)

被引：0
|
作者：
Dobscha, Katherine [1 ]
Wei, Ge [1 ]
Dambkowski, Carl [1 ]
Rogoff, Daniela [1 ]
机构：
[1] QED Therapeut Inc, San Francisco, CA USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-726
引用
收藏
页码：273 / 273
页数：1
相关论文
共 41 条
  • [1] A literature review of the potency and selectivity of FGFR-selective tyrosine kinase inhibitors, such as infigratinib, in the potential treatment of achondroplasia
    Dobscha, Katherine
    Wei, Ge
    Dambkowski, Carl
    Rogoff, Daniela
    HORMONE RESEARCH IN PAEDIATRICS, 2021, 94 (SUPPL 1): : 331 - 332
  • [2] Low-dose infigratinib, an oral selective fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor (TKI), demonstrates activity in preclinical models of achondroplasia (ACH)
    Demuynck, B.
    Flipo, J.
    Li, G.
    Dambkowski, C.
    Legeai-Mallet, L.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 88 - 89
  • [3] Low-dose infigratinib, an oral selective fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, demonstrates activity in preclinical models of FGFR3-related disorders
    Muslimova, Elena
    Demuynck, Benoit
    Loisay, Lea
    Dambkowski, Carl
    Legeai-Mallet, Laurence
    HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 (SUPPL 2): : 29 - 29
  • [4] Efficacy and safety of selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors in FGFR-altered urothelial carcinoma
    Song, Yuxuan
    Du, Yiqing
    Jiang, Shan
    Peng, Yun
    Luo, Xing
    Xu, Tao
    PHARMACOLOGICAL RESEARCH, 2025, 211
  • [5] LATEST NEWS - ACHONDROPLASIA IS ASSOCIATED WITH A MUTATION IN THE MEMBRANE DOMAIN OF FGFR3, THE FIBROBLAST GROWTH-FACTOR RECEPTOR
    DREYFUS, JC
    ROUSSEAU, F
    BONAVENTURE, J
    LEMERRER, M
    MUNNICH, A
    M S-MEDECINE SCIENCES, 1994, 10 (8-9): : 936 - 937
  • [6] Mutations in the fibroblast growth factor receptor 3 (FGFR3) cause achondroplasia, hypochondroplasia, and thanatophoric dysplasia: Taiwanese data
    Tsai, FJ
    Tsai, CH
    Chang, JG
    Wu, JY
    AMERICAN JOURNAL OF MEDICAL GENETICS, 1999, 86 (03): : 300 - 301
  • [7] Fibroblast growth factor receptor 3 (FGFR3) gene G1138A mutation in Chinese patients with achondroplasia
    Wang, TR
    Wang, WP
    Hou, WL
    Lee, ML
    HUMAN MUTATION, 1996, 8 (02) : 178 - 179
  • [8] The achondroplasia mutation occurs exclusively on the paternally derived fibroblast growth factor receptor 3 (FGFR3) allele.
    Szabo, JK
    Wilkin, DJ
    Cameron, R
    Henderson, S
    Bellus, G
    Kaitila, I
    Loughlin, J
    Munnich, A
    Sykes, B
    Bonaventure, J
    Francomano, CA
    AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (04) : A348 - A348
  • [9] Hypochondroplasia, achondroplasia, and thanatophoric dysplasia caused by mutations of the fibroblast-growth-factor-receptor-3-gene (FGFR3)
    Hilbert, M
    Hilbert, K
    Spranger, J
    Wildhardt, G
    Winterpacht, A
    Wuchner, C
    Zabel, B
    MONATSSCHRIFT KINDERHEILKUNDE, 1998, 146 (07) : 687 - 691
  • [10] Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance
    V Chell
    K Balmanno
    A S Little
    M Wilson
    S Andrews
    L Blockley
    M Hampson
    P R Gavine
    S J Cook
    Oncogene, 2013, 32 : 3059 - 3070
12345